A Northern Kentucky startup developing targeted therapies for cancer has dosed its first patient in a clinical study being held in Cincinnati.
Covington-based Bexion Pharmaceuticals, a clinical-stage biopharma company, said Tuesday it dosed its first adult patient in the new study for BXQ-350, its lead drug candidate.
The study, known as RETRO, will assess the potential for BXQ-350 to reduce the intensity and/or duration of chemotherapy-induced peripheral neuropathy, or CIPN, a common side effect…
